Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998990 | 0.88 | PDE10A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL15476104 | 0.88 | PDE10A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL928411 | 0.88 | PDE10A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL2333928 | 0.85 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL1433407 | 0.81 | TRPV1 (0.57) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL30778281 | 0.81 | TRPV1 (0.57) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL25182135 | 0.81 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL31104968 | 0.81 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL6735301 | 0.80 | GPR119 (0.42) | KMT2AMEN1KDM4EGPR119PDE10A | |
| SCHEMBL23603467 | 0.79 | CNR1 (0.47) | KMT2AMEN1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397365-B1 | HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH AS (DK) | 2005-02-16 | — | — | EP | disclosed |
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | NEUROSEARCH A/S (DK) | 2004-07-29 | — | — | US | disclosed |
| EP-1397365-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NeuroSearch A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096911-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH A/S (DK) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | CHRNA3, CHRNA5, CHRNA2 | KMT2A 2597/4885MEN1 4197/4885SMN1; SMN2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.